CB-839, a potent, selective, and orally bioavailable GLS1 inhibitor, has been reported to exhibit significant antiproliferative activity in multiple cancer cell lines and has shown an antitumor effect in tumor xenografts and cancer patients [102]. Here, GLS is linked to neoplasm.